Plain-English translation of NCT06165068 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether aspirin or — medications that thin the blood — can help slow the progression of dry age-related macular degeneration, a condition where deposits build up in the back of the eye and can affect vision. Some participants will take the medication alone, while others will take it combined with an antioxidant supplement called . The study wants to see if these treatments can protect your eyesight.
Dry age-related macular degeneration is a common cause of vision loss in older adults, and there are limited treatment options to slow its progression. Researchers believe that this medication and antioxidant combination might help prevent the condition from worsening, but this hasn't been thoroughly tested yet.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of three groups: one group will take only a low-dose blood thinner (aspirin or ), one group will take the blood thinner plus an antioxidant supplement daily, and one group will take no study medication. Throughout the study, you'll have regular eye imaging scans and vision tests to see how your condition changes. The study team will monitor your progress over time to determine if the medication helps slow the buildup of deposits in your eyes.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Thailand